BIOMAT Database Logo BIOMAT Database Logo

Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme. 2004

Isaac Yang, and Thomas J Kremen, and Adrian J Giovannone, and Elena Paik, and Sylvia K Odesa, and Robert M Prins, and Linda M Liau
UCLA Division of Neurosurgery, University of California at Los Angeles School of Medicine, Los Angeles, California 90095-6901, USA.

OBJECTIVE Little is known about the quantitative modulation of major histocompatibility complex (MHC) Class I expression on human gliomas that is effected by interferons; even less is known about the immunogenic peptides that are accommodated in the peptide-binding motifs of MHC Class I alleles in these brain tumors. In this article the authors investigated the ability of interferon (IFN)alpha and IFNgamma to upregulate MHC Class I expression and to modulate acid-eluted Class I-bound peptides on human glioblastoma multiforme (GBM) cells in vitro. METHODS Early-passage primary human GBM cell cultures and U87MG GBM cells were incubated with varying doses of INFalpha or IFNgamma ranging between 0 and 2000 U/ml. Upregulation of MHC Class I expression was assayed by immunocytochemical analysis, flow cytometry, and Western blot analysis. Modulation of acid-eluted MHC Class I-bound peptides from the IFN-treated GBM cells was examined with the aid of mass spectroscopy. The in vitro expression of the MHC Class I molecule was upregulated by both IFNalpha and IFNgamma in a dose-dependent manner. Interferon-gamma exhibited a more potent effect on MHC Class I upregulation, peaking at 10 U/ml; whereas the effect of IFNalpha was less marked, reaching a plateau at 500 U/ml. In addition, a native peptide eluted from MHC Class I molecules of human GBM cells was identified and found to be consistently upregulated by IFN treatment. CONCLUSIONS Interferon-alpha and IFN-gamma can significantly upregulate the MHC Class I molecules that are expressed on the cell surface of human GBM cells as well as the potentially immunogenic peptides bound to the MHC. These results may help explain the molecular basis for increased immunogenicity with IFN treatment of human GBMs and might provide added insight into the design of future antitumor vaccines for human brain tumors.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D005805 Genes, MHC Class I Genetic loci in the vertebrate major histocompatibility complex which encode polymorphic characteristics not related to immune responsiveness or complement activity, e.g., B loci (chicken), DLA (dog), GPLA (guinea pig), H-2 (mouse), RT-1 (rat), HLA-A, -B, and -C class I genes of man. Class I Genes,Genes, Class I,Genes, H-2 Class I,Genes, HLA Class I,MHC Class I Genes,H-2 Class I Genes,HLA Class I Genes,Class I Gene,Gene, Class I,Genes, H 2 Class I,H 2 Class I Genes
D005909 Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. Astrocytoma, Grade IV,Giant Cell Glioblastoma,Glioblastoma Multiforme,Astrocytomas, Grade IV,Giant Cell Glioblastomas,Glioblastoma, Giant Cell,Glioblastomas,Glioblastomas, Giant Cell,Grade IV Astrocytoma,Grade IV Astrocytomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D015395 Histocompatibility Antigens Class I Membrane glycoproteins consisting of an alpha subunit and a BETA 2-MICROGLOBULIN beta subunit. In humans, highly polymorphic genes on CHROMOSOME 6 encode the alpha subunits of class I antigens and play an important role in determining the serological specificity of the surface antigen. Class I antigens are found on most nucleated cells and are generally detected by their reactivity with alloantisera. These antigens are recognized during GRAFT REJECTION and restrict cell-mediated lysis of virus-infected cells. Class I Antigen,Class I Antigens,Class I Histocompatibility Antigen,Class I MHC Protein,Class I Major Histocompatibility Antigen,MHC Class I Molecule,MHC-I Peptide,Class I Histocompatibility Antigens,Class I Human Antigens,Class I MHC Proteins,Class I Major Histocompatibility Antigens,Class I Major Histocompatibility Molecules,Human Class I Antigens,MHC Class I Molecules,MHC-I Molecules,MHC-I Peptides,Antigen, Class I,Antigens, Class I,I Antigen, Class,MHC I Molecules,MHC I Peptide,MHC I Peptides,Molecules, MHC-I,Peptide, MHC-I,Peptides, MHC-I
D015854 Up-Regulation A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Up-Regulation,Upregulation,Up-Regulation (Physiology),Up Regulation
D015870 Gene Expression The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION. Expression, Gene,Expressions, Gene,Gene Expressions
D016543 Central Nervous System Neoplasms Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges. CNS Neoplasm,CNS Neoplasms,Central Nervous System Neoplasm,Central Nervous System Tumor,Neoplasms, Central Nervous System,Primary Central Nervous System Neoplasm,Central Nervous System Neoplasms, Primary,Central Nervous System Tumors,Primary Central Nervous System Neoplasms,Tumors, Central Nervous System,Neoplasm, CNS,Neoplasms, CNS

Related Publications

Isaac Yang, and Thomas J Kremen, and Adrian J Giovannone, and Elena Paik, and Sylvia K Odesa, and Robert M Prins, and Linda M Liau
Differentiation-stage specific self-peptides bound by major histocompatibility complex class I molecules.
March 1993, The Journal of experimental medicine,
Isaac Yang, and Thomas J Kremen, and Adrian J Giovannone, and Elena Paik, and Sylvia K Odesa, and Robert M Prins, and Linda M Liau
Peptides bound to major histocompatibility complex molecules.
January 1998, Peptides,
Isaac Yang, and Thomas J Kremen, and Adrian J Giovannone, and Elena Paik, and Sylvia K Odesa, and Robert M Prins, and Linda M Liau
Analysis of the structure of naturally processed peptides bound by class I and class II major histocompatibility complex molecules.
January 1995, EXS,
Isaac Yang, and Thomas J Kremen, and Adrian J Giovannone, and Elena Paik, and Sylvia K Odesa, and Robert M Prins, and Linda M Liau
Inhibition of interferon-gamma-induced major histocompatibility complex class I expression by certain oligodeoxynucleotides.
February 1994, Transplantation,
Isaac Yang, and Thomas J Kremen, and Adrian J Giovannone, and Elena Paik, and Sylvia K Odesa, and Robert M Prins, and Linda M Liau
Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma.
January 1996, The Journal of urology,
Isaac Yang, and Thomas J Kremen, and Adrian J Giovannone, and Elena Paik, and Sylvia K Odesa, and Robert M Prins, and Linda M Liau
Tissue-specific self-peptides bound by major histocompatibility complex class I molecules of a human pancreatic beta-cell line.
December 1996, Diabetes,
Isaac Yang, and Thomas J Kremen, and Adrian J Giovannone, and Elena Paik, and Sylvia K Odesa, and Robert M Prins, and Linda M Liau
Interaction of major histocompatibility complex molecules with immunogenic peptides.
January 1988, Current opinion in immunology,
Isaac Yang, and Thomas J Kremen, and Adrian J Giovannone, and Elena Paik, and Sylvia K Odesa, and Robert M Prins, and Linda M Liau
Tissue-specific expression of self peptides bound by major histocompatibility complex class II molecules.
January 1993, Chemical immunology,
Isaac Yang, and Thomas J Kremen, and Adrian J Giovannone, and Elena Paik, and Sylvia K Odesa, and Robert M Prins, and Linda M Liau
Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo.
July 1999, The Journal of experimental medicine,
Isaac Yang, and Thomas J Kremen, and Adrian J Giovannone, and Elena Paik, and Sylvia K Odesa, and Robert M Prins, and Linda M Liau
A quantitative assay to measure the interaction between immunogenic peptides and purified class I major histocompatibility complex molecules.
February 1994, European journal of immunology,
Copied contents to your clipboard!